Compare IPWR & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPWR | CYPH |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.4M | 73.3M |
| IPO Year | 2013 | 2019 |
| Metric | IPWR | CYPH |
|---|---|---|
| Price | $4.00 | $3.61 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.75 | N/A |
| AVG Volume (30 Days) | 181.7K | ★ 16.1M |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 103.87 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,500,000.00 |
| Revenue This Year | $2,603.56 | N/A |
| Revenue Next Year | $1,800.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.62 | $0.49 |
| 52 Week High | $9.30 | $4.19 |
| Indicator | IPWR | CYPH |
|---|---|---|
| Relative Strength Index (RSI) | 39.93 | 58.39 |
| Support Level | $3.78 | $0.69 |
| Resistance Level | $4.49 | $3.23 |
| Average True Range (ATR) | 0.33 | 0.50 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 11.36 | 53.86 |
Ideal Power Inc is engaged in the development of its broadly patented bidirectional power switches, creating efficient and ecofriendly energy control solutions for electric vehicles, electric vehicle charging, renewable energy, energy storage, UPS / data center, solid-state circuit breaker and other industrial and military applications. The company is focused on its patented Bidirectional, Bipolar Junction Transistor (B-TRAN) semiconductor technology. B-TRAN is a double-sided bidirectional AC switchable to deliver substantial performance improvements over conventional power semiconductors. The primary raw material used in the fabrication of B-TRAN devices is silicon wafers.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.